C J G van den Hurk1, W P M Breed, J W R Nortier. 1. Research Department, Eindhoven Cancer Registry/Comprehensive Cancer Centre South, PO Box 231, 5600 AE Eindhoven, The Netherlands. c.vd.hurk@ikz.nl
Abstract
PURPOSE: The patient impact of chemotherapy-induced alopecia (CIA) is high. Scalp cooling is applied to reduce CIA. The potential optimum post-infusion cooling times (PICTs) are currently unknown. METHODS: Scalp cooling was applied in 53 patients receivingdocetaxel chemotherapy with 90-min PICT (observational part). Also 15 non-scalp-cooled patients were included. If hair preservation was observed in >80 % of the patients, randomisation between 45 and 90-min PICT was planned. Patients reported tolerance of scalp cooling and use of head covering. RESULTS:Observational study: 81 % of scalp-cooled patients did not require head covering versus 27 % of non-scalp-cooled patients. Randomised study: 79 % of 38 patients with 90-min PICT did not need head covering versus 95 % of 38 patients with 45-min PICT (p = 0.04). Scalp cooling was very well tolerated (visual analogue scale = 79). CONCLUSION: A 45-min PICT can be recommended in 3-weekly docetaxel regimens with a dose of 75 or 100 mg/m(2), administered in 60 min. The shorter PICT is a major advantage in time investment for patients. Patients (women and men) who receivedocetaxel, except combined with doxorubicin and cyclophosphamide (taxotere, adriamycin and cyclophosphamide (TAC)) should be informed about the protective effect and high tolerability of scalp cooling in avoiding CIA.
RCT Entities:
PURPOSE: The patient impact of chemotherapy-induced alopecia (CIA) is high. Scalp cooling is applied to reduce CIA. The potential optimum post-infusion cooling times (PICTs) are currently unknown. METHODS:Scalp cooling was applied in 53 patients receiving docetaxel chemotherapy with 90-min PICT (observational part). Also 15 non-scalp-cooled patients were included. If hair preservation was observed in >80 % of the patients, randomisation between 45 and 90-min PICT was planned. Patients reported tolerance of scalp cooling and use of head covering. RESULTS: Observational study: 81 % of scalp-cooled patients did not require head covering versus 27 % of non-scalp-cooled patients. Randomised study: 79 % of 38 patients with 90-min PICT did not need head covering versus 95 % of 38 patients with 45-min PICT (p = 0.04). Scalp cooling was very well tolerated (visual analogue scale = 79). CONCLUSION: A 45-min PICT can be recommended in 3-weekly docetaxel regimens with a dose of 75 or 100 mg/m(2), administered in 60 min. The shorter PICT is a major advantage in time investment for patients. Patients (women and men) who receive docetaxel, except combined with doxorubicin and cyclophosphamide (taxotere, adriamycin and cyclophosphamide (TAC)) should be informed about the protective effect and high tolerability of scalp cooling in avoiding CIA.
Authors: J Sjöström; C Blomqvist; H Mouridsen; A Pluzanska; S Ottosson-Lönn; N O Bengtsson; B Ostenstad; I Mjaaland; M Palm-Sjövall; E Wist; V Valvere; H Anderson; J Bergh Journal: Eur J Cancer Date: 1999-08 Impact factor: 9.162
Authors: S Chan; K Friedrichs; D Noel; T Pintér; S Van Belle; D Vorobiof; R Duarte; M Gil Gil; I Bodrogi; E Murray; L Yelle; G von Minckwitz; S Korec; P Simmonds; F Buzzi; R González Mancha; G Richardson; E Walpole; M Ronzoni; M Murawsky; M Alakl; A Riva; J Crown Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: P M Ravdin; H A Burris; G Cook; P Eisenberg; M Kane; W A Bierman; J Mortimer; E Genevois; R E Bellet Journal: J Clin Oncol Date: 1995-12 Impact factor: 44.544
Authors: Hope S Rugo; Paula Klein; Susan Anitra Melin; Sara A Hurvitz; Michelle E Melisko; Anne Moore; Glen Park; Jules Mitchel; Erika Bågeman; Ralph B D'Agostino; Elizabeth S Ver Hoeve; Laura Esserman; Tessa Cigler Journal: JAMA Date: 2017-02-14 Impact factor: 56.272
Authors: Christopher John Dunnill; Wafaa Al-Tameemi; Andrew Collett; Iain Stuart Haslam; Nikolaos Theodoros Georgopoulos Journal: Oncologist Date: 2017-09-26
Authors: Manon M C Komen; Corina J G van den Hurk; Johan W R Nortier; Tjeerd van der Ploeg; P Nieboer; Jacobus J M van der Hoeven; Carolien H Smorenburg Journal: Support Care Cancer Date: 2018-09-11 Impact factor: 3.603
Authors: Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture Journal: Eur J Dermatol Date: 2016-10-01 Impact factor: 3.328
Authors: Joanne M Shaw; Jane O'Brien; Susan Chua; Richard De Boer; Rachel Dear; Nicholas Murray; Fran Boyle Journal: Support Care Cancer Date: 2017-08-29 Impact factor: 3.603
Authors: Manon M C Komen; Wim P M Breed; Carolien H Smorenburg; Tjeerd van der Ploeg; S H Goey; Jacobus J M van der Hoeven; Johan W R Nortier; Corina J G van den Hurk Journal: Support Care Cancer Date: 2016-01-25 Impact factor: 3.603
Authors: Daniel C Betticher; Geoffrey Delmore; Urs Breitenstein; Sandro Anchisi; Beatrice Zimmerli-Schwab; Andreas Müller; Roger von Moos; Anne Marguerite Hügli-Dayer; Hubert Schefer; Sereina Bodenmann; Vera Bühler; Ralph R Trueb Journal: Support Care Cancer Date: 2013-05-02 Impact factor: 3.603